Role of afatinib in the treatment of advanced lung squamous cell carcinoma - PubMed (original) (raw)
Review
Role of afatinib in the treatment of advanced lung squamous cell carcinoma
Tiziana Vavalà. Clin Pharmacol. 2017.
Abstract
Lung cancer treatment has considerably changed over the last few years: the identification of druggable oncogenic alterations and innovative immunotherapic approaches granted lung cancer patients the possibility of more efficient and less toxic therapeutic options than chemotherapy. Nowadays, lung squamous cell carcinomas (SqCCs) patients have the chance to benefit from novel treatment alternatives, including immune checkpoint blockade and anti-angiogenic agents and, given positive trial results, from afatinib, a second generation tyrosine kinase inhibitor (TKI) that irreversibly antagonizes ErbB family tyrosine kinase receptors. Considering the role of the ErbB-signaling cascade in lung SqCC, it is relevant to note that ErbB1 (epidermal growth factor receptor [EGFR]) is overexpressed in 85% of non-small-cell lung carcinomas (NSCLCs), particularly in patients with squamous histology, and is associated with poor prognosis. For this reason, EGFR activity has been investigated as a therapeutic strategy in lung SqCC. Even taking into account statistically positive trial results, anti-EGFR approach still remains controversial in unselected/wild-type EGFR lung SqCC patients, as well as the optimal timing and sequencing of all available targeted therapies considering the approval of immunotherapeutic agents. This review analyzes current data about EGFR inhibition in lung SqCC with a specific focus on afatinib in order to elucidate available clinical evidence supporting EGFR targeting in this setting as well as a future management of advanced lung SqCCs in the context of new emerging immunotherapeutic drugs.
Keywords: EGFR; LUX-Lung; NSCLC; TKI; lung cancer; tyrosine kinase inhibitor.
Conflict of interest statement
Disclosure The author reports no conflicts of interest in this work.
Similar articles
- New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.
Hirsh V. Hirsh V. Onco Targets Ther. 2017 May 11;10:2513-2526. doi: 10.2147/OTT.S104177. eCollection 2017. Onco Targets Ther. 2017. PMID: 28546756 Free PMC article. Review. - [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
Wislez M, Malka D, Bennouna J, Mortier L, Bensadoun RJ, Sicard J, Dielenseger P, Rey JB, Moro-Sibilot D, Scotté F. Wislez M, et al. Bull Cancer. 2014 Jun;101(6):647-52. doi: 10.1684/bdc.2014.1986. Bull Cancer. 2014. PMID: 24977454 French. - Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib.
Lu S. Lu S. Onco Targets Ther. 2019 Feb 22;12:1521-1538. doi: 10.2147/OTT.S188296. eCollection 2019. Onco Targets Ther. 2019. PMID: 30863118 Free PMC article. Review. - [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
Cobo M, Gutiérrez V, Rodelo L, López O, Ruiz M, Godoy A. Cobo M, et al. Med Clin (Barc). 2016 Apr;146 Suppl 1:25-9. doi: 10.1016/S0025-7753(16)30260-3. Med Clin (Barc). 2016. PMID: 27426245 Review. Spanish. - Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D, Popat S. Marquez-Medina D, et al. Future Oncol. 2015 Sep;11(18):2525-40. doi: 10.2217/fon.15.183. Epub 2015 Aug 28. Future Oncol. 2015. PMID: 26314834 Review.
Cited by
- Docking and Selectivity Studies of Covalently Bound Janus Kinase 3 Inhibitors.
Zhong HA, Almahmoud S. Zhong HA, et al. Int J Mol Sci. 2023 Mar 23;24(7):6023. doi: 10.3390/ijms24076023. Int J Mol Sci. 2023. PMID: 37047004 Free PMC article. - "From molecular to clinic": The pivotal role of CDC42 in pathophysiology of human papilloma virus related cancers and a correlated sensitivity of afatinib.
Wei E, Li J, Anand P, French LE, Wattad A, Clanner-Engelshofen B, Reinholz M. Wei E, et al. Front Immunol. 2023 Mar 1;14:1118458. doi: 10.3389/fimmu.2023.1118458. eCollection 2023. Front Immunol. 2023. PMID: 36936942 Free PMC article. - SP3-FAIMS Chemoproteomics for High-Coverage Profiling of the Human Cysteinome*.
Yan T, Desai HS, Boatner LM, Yen SL, Cao J, Palafox MF, Jami-Alahmadi Y, Backus KM. Yan T, et al. Chembiochem. 2021 May 14;22(10):1841-1851. doi: 10.1002/cbic.202000870. Epub 2021 Feb 18. Chembiochem. 2021. PMID: 33442901 Free PMC article. - Identification of 4-anilino-6-aminoquinazoline derivatives as potential MERS-CoV inhibitors.
Lee JY, Shin YS, Lee J, Kwon S, Jin YH, Jang MS, Kim S, Song JH, Kim HR, Park CM. Lee JY, et al. Bioorg Med Chem Lett. 2020 Oct 15;30(20):127472. doi: 10.1016/j.bmcl.2020.127472. Epub 2020 Aug 8. Bioorg Med Chem Lett. 2020. PMID: 32781216 Free PMC article. - Concurrent inhibition of ErbB family and MEK/ERK kinases to suppress non-small cell lung cancer proliferation.
Lin X, Liao J, Geng X, Dan H, Chen L. Lin X, et al. Am J Transl Res. 2020 Mar 15;12(3):847-856. eCollection 2020. Am J Transl Res. 2020. PMID: 32269717 Free PMC article.
References
- WHO Statistics.int [webpage on the Internet] [Accessed July 21, 2017]. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/
- Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32:669–692. - PubMed
- Vavalà T, Novello S. SC10.04 second-line therapy and beyond in squamous cell NSCLC. J Thorac Oncol. 2017;12(1):S101–S102.
- Hirsch FR, Varella-Garcia M, Bunn PA, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21(20):3798–3807. - PubMed
- López-Malpartida AV, Ludeña MD, Varela G, García Pichel J. Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas. Lung Cancer. 2009;65(1):25–33. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous